Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurological and Pain Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CACNA1E (CaV2.3) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CACNA1E ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CACNA1E Products |
| Gene Delivery | CACNA1E Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Essential for calcium flux assays. HEK293 Expressed, Endotoxin Controlled. |
View CACNA1E Products |
| Stable Cell Line | CACNA1E-HEK293 Stable Cell Pool Pre-validated for electrophysiology and calcium flux assays. Sequence Verified. |
View CACNA1E Products |
| Benchmark Ab | Anti-CACNA1E Benchmark Antibody Recombinant positive control for assay normalization. |
View CACNA1E Products |
| Validator | CACNA1E siRNA Set For knockdown verification and specificity checks. |
View CACNA1E Products |
| Ortholog Panel | CACNA1E (Cyno/Mouse/Rat) Lentivirus Cross-species evaluation for translational toxicology. |
View CACNA1E Products |
| Related Target A | CACNA1A (CaV2.1) Crucial subfamily counter-screening target to prevent off-target CNS toxicity. |
View CACNA1A Products |
| Related Target B | CACNA1B (CaV2.2) Synergistic pain pathway target and essential selectivity control. |
View CACNA1B Products |
| Related Target C | CACNA1C (CaV1.2) Cardiovascular safety liability screening (L-type). |
View CACNA1C Products |
| Related Target D | CACNB3 (Calcium Channel Beta-3 Subunit) Auxiliary subunit modulating trafficking and kinetics. |
View CACNB3 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Membrane Protein Conformation | Lentivirus-mediated stable cell line construction for native multi-pass folding; preserves native glycosylation and auxiliary subunit compatibility. |
| State-dependent pharmacology (Resting vs. Inactivated) | Native conformation preservation via full-length channel in mammalian membrane; compatible with automated patch-clamp (QPatch/SyncroPatch) platforms. |
| Subfamily Off-Target Screening | Sequence Verified homolog panels (CACNA1A, CACNA1B, CACNA1C, CACNA1D) for absolute selectivity; >95% Sequence Identity verification. |
| Functional calcium flux validation | Stable cell lines optimized for FLIPR Calcium 6 and Imaging Plate Reader formats; Endotoxin <1 EU/μg ensuring minimal basal calcium activation. |
| Peripheral vs. CNS penetration screening | Human/Mouse/Cyno orthologs available for blood-brain barrier model compatibility and translational PK/PD bridging. |
| Lack of Reliable Controls | Recombinant Benchmark Antibodies strictly sequence verified; Validated siRNA included for background signal verification. |
Live CACNA1E R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The CACNA1E target landscape has shifted from broad-spectrum analgesics to precision neurology. Following the discontinuation of first-generation small-molecule inhibitors (e.g., Pfizer's PF-06305591) for chronic pain in 2018, the field pivoted toward genetic validation: rare de novo CACNA1E gain-of-function mutations (e.g., rs1553286282, rs2102063243, rs886039323 associated with Developmental and Epileptic Encephalopathy, DEE69) now define a specific subtype of epilepsy. As a critical R-type voltage-gated calcium channel encoded by CACNA1E, CaV2.3 is highly implicated in pain pathways, epilepsy, and Parkinson's disease. The current R&D wave focuses on state-dependent channel blockers with peripheral selectivity for pain, and antisense oligonucleotides (ASOs) for monogenic epilepsy. As second-generation modulators enter preclinical development, the critical differentiator is selectivity over the cardiac L-type (CaV1.2) and neuronal N-type (CaV2.2) channels to avoid cardiovascular and autonomic liabilities. The channel contains an EF-hand domain important for calcium-dependent regulation, and mutations in this region can alter channel gating.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (State-dependent Blocker) | Specialty neuroscience biotechs; academic consortia | Chronic Pain (Osteoarthritis, Neuropathic), Epilepsy (DEE69) | Automated Patch-Clamp on Stable Cell Lines (require full-length membrane integration) |
| Antisense Oligonucleotide (ASO) | Genetic therapy biotechs | Developmental Epileptic Encephalopathy (Gain-of-Function Mutations) | Knockdown Validation Assays (siRNA included as positive control) |
| Biologic (Monoclonal Antibody) / Peptide | Preclinical exploration | Peripheral Pain (localized), Rare Epilepsies | Extracellular Domain Binding (ECD-Fc constructs for ELISA/SPR); Native conformation needed |